Moving to Clinical Lab 2.0
Deliver more Value!
Get Paid More Dollars!
James M Crawford, MD, PhD
[email protected]
Executive Director and Senior Vice President for Laboratory Services,
Northwell Health
Professor and Chair, Pathology/Lab Medicine
Hofstra Northwell School of Medicine
Manhasset, NY
1
Disclosures
• ClaraPath (start up from Cold Spring Harbor Laboratories)*
─ 2015: Technical Advisory Committee
• Northwell Health Genomics Alliance (with OPKO Health)
─ 2015: President of LLC
*Technology Transfer
2
What is “Clinical Lab 2.0”
• Transactional Lab Data
→
Integrative Information
• Reactive: Order/Result
→
Proactive: Need/Information
• Lab = Commodity
→
Lab = Essential system asset
• Technical experts only
→
SME on Health Care delivery
• We don’t look at our own data →
We are the experts on what our data mean
Identification of Risk
Escalation of Health Care
Gaps-in-Care
Outcomes (or not)
Predicative Analytics
We can help drive financial health of system
3
Who are our Stakeholders?
• Those who pay for our information:
Payers
Health system
Employers
• Those who make health care decisions: Providers
Consumers
“Value” is what someone is willing to pay for.
Listen to their needs.
Are we meeting their needs?
Prove it.
4
“Clinical Lab 2.0” is Leadership,
not Followship
5
What are we responding to?
Downside
• Under-appreciation by our Stakeholders
• Under-utilization of our expertise
• Risk of not controlling our destiny
Upside
• Extraordinary opportunity to provide better health care
• Unrealized opportunity to support better financial outcomes for
our Stakeholders
*ABN, Advanced Beneficiary Notice
6
Objectives of this Workshop
•
•
•
•
To identify measures of Success for a “2.0” clinical laboratory
To understand the strategies for getting there
To learn tactical approaches from review of examples
To share in lessons learned
7
“THERE”
“HERE”
8
“THERE”
“HERE”
Be Intrusive
Be Insistent
Be Creative
Learn new Skills
Build new Teams
Take Risks!
9
Where is the Opportunity?
“Innovation” in detail
• Inpatient: AKI, antibiotic stewardship, sepsis bundles….
• Outpatient: CKD, diabetes, anti-coagulation….
“Innovation” at global level
• Disease Management teams
• Precision Medicine
Financial Performance
• Not your “3%” – the other 97%
• Impact of Lab on the Total Health Care Spend
• Impact of Lab on the Total Revenue Cycle
10
10
Clinical Lab 1.0
Lab
Stakeholder
Outcome
11
Clinical Lab 2.0
Lab
Stakeholder
Outcome
12
The Structure of Today’s Workshop
•
•
•
•
Khosrow Shotorbani:
Why is Clinical Lab 2.0 different?
Tarush Kothari, MD, MPH:
Success story with AKI
Ilan Rubinfeld, MD:
Health System CMO perspective
Monique Dodd, DPharm/
Building the Value Statements
Kathleen Swanson, MS, RPh
• Aron Seidman
Changing IT infrastructure
• Informatics Panel
• Open Q&A Session
13
[email protected]
14